Efficacy and Safety of Immunoglobulin Intravenous (Human) 10% (NewGam) in Primary Immune Thrombocytopenia
Status:
Completed
Trial end date:
2013-07-01
Target enrollment:
Participant gender:
Summary
NewGam is a newly developed human normal immunoglobulin solution for intravenous
administration (IGIV). This study will evaluate the safety and efficacy of NewGam 10% in
patients with primary immune thrombocytopenia.